| abstract |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the major substituents have the following meanings: R is H or CH 2 -Ph, R 1 is -Het, -N - [(CH 2) ) 5-OH] 2, -N- [CH 2) S-OA] 2, -NH- (CH 2) S -Ar, -Het- (CH 2) n -Ar or -Het-Het; R 2 is H, OH, COOH,, CH (Ph) -Ph, or Ar; Ar is phenyl, cycloalkyl, naphthyl, cyclohex-1-phenyl, biphenyl, bicyclohexyl, 4-cyclohexyl-phenyl, benzo [1,3] dioxol-5-yl Het is a saturated or partially or unsaturated mono- or bicyclic heterocyclic group having 5 to 10 ring members, wherein 1 or 2 N and / or 1 or 2 S or O atoms may be present; i is 1, 2, 3, 4, 5 , 6, 7, 8, 9, 10, 11, or 12. The compounds of the present invention never act as glycoprotein IbIX antagonists, and include pharmaceutical compositions containing the compounds. |